Sep 9, 2025 7:00 am EDT New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett’s Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions
Aug 25, 2025 7:00 am EDT New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
Jul 29, 2025 7:00 am EDT Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
Jul 25, 2025 7:00 am EDT Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
Jul 23, 2025 7:00 am EDT FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
Jul 17, 2025 7:00 am EDT Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
Jul 14, 2025 7:00 am EDT Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
Jun 19, 2025 7:00 am EDT Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
